First FDA-Authorized COVID-19 Vaccine Hits U.S. This Week!
FDA Commissioner Stephen M. Hahn, M.D. says:
The FDA’s authorization for emergency use of the first COVID-19 vaccine is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world.
Alex Reid here with your Monday roundup.
Just last week, the U.S. Food and Drug Administration (FDA) approved the Pfizer-BioNTech coronavirus vaccine for emergency use.
With numbers at an all-time high, there are currently over 72 million COVID-19 cases worldwide and over 16 million in the United States.
On the heels of the FDA’s authorization, Pfizer will send over 2.9 million doses to all 50 states this week.
On December 11, Dr. Hahn spoke on the historic move:
Today’s action follows an open and transparent review process that included input from independent scientific and public health experts and a thorough evaluation by the agency’s career scientists to ensure this vaccine met FDA’s rigorous, scientific standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization.
The tireless work to develop a new vaccine to prevent this novel, serious, and life-threatening disease in an expedited time frame after its emergence is a true testament to scientific innovation and public-private collaboration worldwide.
Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, chimed in on the FDA’s decision:
While not an FDA approval, today’s emergency use authorization of the Pfizer-BioNTech COVID-19 Vaccine holds the promise to alter the course of this pandemic in the United States.
While the vaccine hasn’t been approved for children, it’s designed it is designed to be taken by those 16 years old and up. According to the FDA, “The data also support that the known and potential benefits outweigh the known and potential risks.”
For this reason, the FDA supports the use of this vaccine for millions of people, including healthy individuals.
More Supporting Studies and the Process
The Pfizer-BioNTech COVID-19 vaccine includes two doses, administered three weeks apart.
The safety data used by the FDA included over 37,000 participants who enrolled in an ongoing randomized, placebo-controlled international study.
Most of these participants were American.
Of the participants, 18,801 received the vaccine while 18,785 participants received a saline placebo.
The study watched the participants for about two months after their second dose.
You can see the results here.
Meanwhile in New Zealand…
Things are looking much different. The country has only recorded 2,096 COVID-19 cases, with 2,015 recoveries and 25 deaths.
More shocking health news: On December 14, the country recorded no new coronavirus cases.
If there's anywhere to hide out during a time like this, New Zealand sounds like the place.
But it won’t be easy — the country has very strict border restrictions.
So the best thing we can do for now is focus on our health.
Drink your water. Get enough sleep. Get the nutrients your body craves.
In fact, give this book of health secrets a look.
To your health, Alex Reid
President, Longevity Insider HQ
To your health,